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ABSTRACT
In recent years, lentiviral expression systems have
gained an unmatched reputation among the gene
therapy community for their ability to deliver thera-
peutic transgenes into a wide variety of dif®cult-to-
transfect/transduce target tissues (brain, hemato-
poietic system, liver, lung, retina) without eliciting
signi®cant humoral immune responses. We have
cloned a construction kit-like self-inactivating lenti-
viral expression vector family which is compatible
to state-of-the-art packaging and pseudotyping
technologies and contains, besides essential cis-
acting lentiviral sequences, (i) unparalleled poly-
linkers with up to 29 unique sites for restriction
endonucleases, many of which recognize 8 bp
motifs, (ii) strong promoters derived from the
human cytomegalovirus immediate-early promoter
(PhCMV) or the human elongation factor 1a (PhEF1a),
(iii) PhCMV± or PPGK± (phosphoglycerate kinase
promoter) driven G418 resistance markers or
¯uorescent protein-based expression tracers and
(iv) tricistronic expression cassettes for coordinated
expression of up to three transgenes. In addition,
we have designed a size-optimized series of highly
modular lentiviral expression vectors (pLenti-
Module) which contain, besides the extensive cen-
tral polylinker, unique restriction sites ¯anking any
of the 5¢U3, R-U5-y+-SD, cPPT-RRE-SA and
3¢LTRDU3 modules or placed within the 5¢U3 (±78 bp)
and 3¢LTRDU3 (8666 bp). pLentiModule enables
straightforward cassette-type module swapping
between lentiviral expression vector family mem-
bers and facilitates the design of Tat-independent
(replacement of 5¢LTR by heterologous promoter
elements), regulated and self-excisable proviruses
(insertion of responsive operators or LoxP in the
3¢LTRDU3 element). We have validated our lentiviral
expression vectors by transduction of a variety of
insect, chicken, murine and human cell lines as well
as adult rat cardiomyocytes, rat hippocampal slices
and chicken embryos. The novel multi-purpose con-
struction kit-like vector series described here is
compatible with itself as well as many other (non-
viral) mammalian expression vectors for straightfor-
ward exchange of key components (e.g. promoters,
LTRs, resistance genes) and will assist the gene
therapy and tissue engineering communities in
developing lentiviral expression vectors tailored for
optimal treatment of prominent human diseases.
INTRODUCTION
Gene therapy strategies rely on ef®cient transfer of therapeutic
transgenes into desired target cells. A variety of viral and non-
viral vectors and expression concepts have been designed and
evaluated for their safety, high-level transduction, tropism and
sustained expression in a variety of therapeutically relevant
cells and tissues (1,2). Retroviral vectors derived from
oncoretroviruses such as the murine leukemia virus (MLV)
emerged as the most widely used gene therapy tools for
transgene delivery currently in the clinics (3). The attractive-
ness of oncoretroviral transduction technologies resides in: (i)
their ability to mediate stable integration in the target
chromosomes likely promoting long-term expression of
delivered transgenes; (ii) their large cloning capacity suf®cient
for most foreseeable clinical situations; (iii) their compatibil-
ity with pseudotyping strategies which extend the tropism of
gene delivery; and (iv) the exclusive delivery of therapeutic
transgenes in the absence of viral genes which precludes any
potent humoral immune response eliminating transduced cells
and enables recurring treatments (3,4).
In addition to these characteristics common to all retro-
viruses, lentiviruses such as the human immunode®ciency
virus type 1 (HIV-1) can replicate in non-mitotic cells owing
to their so-called pre-integration complex, a macromolecular
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structure comprising the viral genome, a few structural
proteins and the enzymes responsible for reverse transcription
and integration (5±7). Transduction of proliferation-incompe-
tent cells is a decisive asset for molecular interventions in
tissues considered key targets for future gene therapy includ-
ing the brain, the heart, the hematopoietic system, the liver, the
lungs and the retina (8±14). Like all retroviruses, the HIV-1
genome contains the gag, pol and env regions, which encode
the core proteins, the virion-associated enzymes and the
envelope (Env) glycoprotein (13,15). This coding region is
¯anked by the long terminal repeats (LTRs; 5¢ and 3¢LTR) and
cis-acting sequences essential for integration, transcription
and polyadenylation. In addition, HIV-1 contains two regu-
latory genes, tat and rev, required for viral replication (LTR
transactivation and nuclear export of viral RNA) and four
accessory genes, vif, vpr, vpu and nef, which are dispensable
for viral growth but critical for in vivo replication and
pathogenesis (15). Basal transcription of the HIV-1 provirus'
5¢LTR initially results in small amounts of multiply spliced
transcripts encoding Tat, Rev and Nef. Tat transactivates
5¢LTR-mediated transcription until Rev reaches a threshold
concentration and mediates cytoplasmic accumulation of
unspliced and singly spliced viral transcripts followed by
production of the late viral proteins (15).
Capitalizing on a re®ned understanding of HIV-1 molecular
biology following decades of intensive research on acquired
immunode®ciencies, a group of researchers pioneered the
transition of this well-evolved pathogen into a high leverage
gene therapy tool (16±18). HIV-1-based vectors have been
generated using a multiply attenuated packaging system,
which is activated in its most advanced third generation
con®guration by transient transfection of four plasmids
encoding: (i) gag (coding for the virion main structural
proteins) and pol (responsible for lentivirus-speci®c
enzymes); (ii) rev (a post-transcriptional regulator for gag
and pol expression as well as nuclear RNA export); (iii) vsv-g
(required for pseudotyping); and (iv) the desired transgene in a
lentiviral expression con®guration (lentiviral expression
vector or lentivector) (19). Latest developments include
packaging cell lines, which express all packaging components
and require exclusive transfection of the lentiviral expression
vector (20±23). The lentiviral expression vector, which can be
combined with any generation of packaging system, is the
only genetic material transferred to the target cell. It typically
comprises the transgene cassette ¯anked by cis-acting
elements required for encapsidation, reverse transcription
and integration including the packaging signal (y+), the
polypurine tracts (PPT), 5¢ and 3¢LTRs as well as env-derived
sequences encompassing the Rev response element (RRE)
(16±19,24). Latest generation HIV-1-based expression tech-
nologies include self-inactivating (SIN) vectors, which loose
the transcriptional capacity of the LTR once integrated into
target cells. SIN vectors show improved performance and are
devoid of transcriptional interference and in vivo suppression
associated with standard vectors and enable construction of
more-stringent tissue-speci®c and/or regulatable expression
con®gurations (25,26).
Unfortunately, current lentiviral expression vectors are the
result of a progressive development rather than a bottom-up
rational design and are therefore often lacking convenient
multiple cloning sites (MCS) and a modular set-up to increase
compatibility with existing expression technologies (gene
regulation, recombination) (16,17,19). This situation has
signi®cantly delayed the dissemination of lentiviral expression
technology beyond the pioneering laboratories to a broad
scienti®c community. We describe here a size-optimized
highly modular construction kit of SIN lentiviral expression
vectors containing extended MCS, multicistronic expression
cassettes as well as various promoter and resistance elements.
MATERIALS AND METHODS
Cell culture and ¯uorescence microscopy
Chinese hamster ovary cells (CHO-K1; ATCC CCL-61), baby
hamster kidney cells BHK-21 (ATCC CCL-10), human
®brosarcoma cells HT-1080 (ATCC CCL-121), human cer-
vical adenocarcinoma cells HeLa (ATCC CCL-2), human
hepatocellular carcinoma cells HepG2 (ATCC HB-8065) and
human chronic myelogenous leukemia cell line K-562
(ATCC-243) were cultivated in FMX-8 (Cell Culture
Technologies GmbH, Switzerland), Dulbecco's modi®ed
Eagle medium (DMEM) (BHK-21, HT-1080, HeLa, HepG2;
catalog no. 52100-039; Life Technologies AG, Basel,
Switzerland) or Iscove's modi®ed Dulbecco's medium (K-
562, catalog no. 4220-022; Life Technologies AG) supple-
mented with 10% fetal calf serum (all other cell lines; PAA
Vienna, Austria; Lot. no. A01129-242). The chicken bursal
cell line DT40 was cultivated as described before (27). Adult
rat cardiomyocytes (ARC) were prepared and cultivated as
described previously (28). Hippocampal slices prepared from
6-day postnatal rats were cultured using the roller-tube
technique (29).
For DRAQ5-mediated DNA-speci®c staining of transduced
cells, 4 3 103 CHO-K1 cells were seeded into chamber slides
(Lab-Tek, Nalge Nunc International, IL) and grown for 24 h
before they were infected with 2 3 106 c.f.u./ml of desired
lentiviruses (pMF365-, pBM40- and pBM45-derived). After
48 h, DRAQ5 (Biostatus Ltd, Leicestershire, UK) was added
to the culture at a ®nal concentration of 25 mM for 7 min. The
medium was removed and cells washed twice with PBS
(Dulbecco's phosphate-buffered saline, Sigma, catalog no.
D5773) before they were ®xed with 4% paraformaldehyde in
PBS for 8 min and washed another ®ve times with PBS. After
removing the PBS, the cells were covered with a drop of
Lisbeth's medium [Tris-buffered glycerol: 3:7 mixture of
0.1 M Tris±HCl (pH 9.5) and glycerol plus 50 mg/ml n-
propyl-gallat] and sealed with a cover slip for confocal
microscopy.
Expression of ¯uorescent proteins was visualized using
a Leica DM-RB ¯uorescence microscope (Heerbrugg,
Switzerland) or a confocal microscope set-up (Zeiss
Axioplan ¯uorescence microscope, Biorad MRC-600 con-
focal scanner, Silicon Graphics workstation) equipped with
appropriate ®lters. The ¯uorescence of the enhanced green
¯uorescent protein (EGFP) and the enhanced yellow ¯uores-
cent protein (EYFP) were visualized using the XF114 ®lter
(Omega Optical Inc., Brattleboro, VT), the enhanced cyan
¯uorescent protein (ECFP) was detected using the XF105
®lter (Omega Optical Inc.) and the red ¯uorescent protein was
monitored using the N2.1 ®lter by Leica Inc (Heerbrugg,
Switzerland).
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Table 1. Plasmids used and constructed in this study
Plasmid Description Reference or source
pcDNA3.1/V5-His
TOPO
Mammalian expression vector Invitrogen, Carlsbad, CA
pcDNA3 Mammalian expression vector vector Invitrogen, Carlsbad, CA
pcDNA3-VEGF121 pcDNA3 encoding human VEGF121 Weber, unpublished
pCF10 Dual-regulated expression vector Fux and Fussenegger,
submitted for publication
pEF4/MycHisB Expression vector containing the human elongation factor 1a promoter (PEF1a ) Invitrogen, Carlsbad, CA
pEYFP-C1 Expression vector encoding the enhanced yellow ¯uorescent protein under control of PhCMV Clontech, Palo Alto, CA
PMSCVneo Retroviral expression vector derived from the murine embryonic stem cell virus Grez et al., 1990
PLPCX Retroviral expression vector derived from the Moloney MLV (MoMuLV) and Moloney
murine sarcoma virus (MoMuSV)
Miller and Rosman, 1989
pNL-EGFP Lentiviral expression vector (5¢LTR-y+-oriSV40-cPPT-RRE-3¢LTR) Mochizuki et al., 1998
pNL-EGFPDU3 pNL-EGFP containing an EcoRV/PvuII deletion in the U3 region of the 3¢LTR
eliminating any enhancers (5¢LTR-y+-oriSV40-cPPT-RRE-3¢LTRDU3)
Reiser et al., unpublished
pSS173 Mammalian expression vector encoding the human placental SEAP Schlatter et al., 2002
pWW85 Triple-¯uorescent expression vector encoding ECFP, RFP and EYFP Weber et al., 2002
pWW265 VEGF121 was excised from pcDNA-VEGF121 by HindIII/SpeI and ligated into the
corresponding sites (HindIII/SpeI) of pCF10 (PhCMV-VEGF121-pA)
Weber et al., unpublished
pTRIDENT1 Tricistronic mammalian expression vector harboring a tetracycline-responsive,
PhCMV*-1-driven expression unit (PhCMV*-1-MCSI-IRESI-MCSII-IRESII-MCSIII-pA) (pMF125)
Fussenegger et al., 1998
pTRIDENT3 Tricistronic mammalian expression vector harboring a tetracycline-responsive,
PhCMV*-1-driven expression unit (PhCMV*-1-MCSI-IRES-MCSII-CITE*-MCSIII-pA) (pMF122)
Fussenegger et al., 1998
pMF201 Dual-regulated expression vector encoding EYFP and ECFP Fussenegger et al., 2000
pMF242 pcDNA3.1/V5-His TOPO encoding mouse erythropoietin (mEPO) Fussenegger et al., 2000
pMF320 PEF1a was ampli®ed from pEF4/MycHisB by OMF164/OMF165 and cloned in
antisense orientation into pcDNA.3.1/V5-His TOPO
This work
pMF351 PhCMV-EYFP was ampli®ed from pEYFP-C1 with OMF179/OMF180 and cloned as HpaI/KpnI
fragment into the corresponding sites (HpaI/KpnI) of pNL-EGFPDU3 (5¢LTR-y+-oriSV40-cPPT-
RRE-MCSI-PhCMV-EYFP-MCSII-3¢LTRDU3)
This work
pMF352 U3 was ampli®ed from pNL-EGFPDU3 using OMF183/OMF184 and cloned into pcDNA3.1/V5-His
TOPO. The U3 fragment contains a Sbf I site
This work
pMF353 R-U5-y+-SD was ampli®ed from pNL-EGFPDU3 using OMF185/OMF186 and cloned into
pcDNA3.1/V5-His TOPO
This work
pMF355 PPT-3¢LTRDU3 was ampli®ed from pNL-EGFPDU3 using OMF189/OMF190 and cloned into
pcDNA3.1/V5-His TOPO
This work
pMF356 The PhCMV-EYFP cassette of pMF351 was excised by NotI and the backbone religated
(5¢LTR-y+-oriSV40-cPPT-RRE-MCS-3¢LTRDU3)
This work
pMF357 U3 was excised from pMF352 by XhoI/SrfI and cloned into the corresponding sites (XhoI/SrfI)
of pTRIDENT1
This work
pMF358 R-U5-y+-SD was excised from pMF353 by SrfI/SwaI and cloned into the corresponding sites
(SrfI/SwaI) of pMF357
This work
pMF358x R-U5-y+-SD was excised from pMF376 by SrfI/SwaI and cloned into the corresponding sites
(SrfI/SwaI) of pMF357
This work
pMF359 PEF1a was excised from pMF320 by EcoRV/XmaI and cloned into the corresponding sites
(HpaI/XmaI) of pMF356 (5¢LTR-y+-oriSV40-cPPT-RRE-PhEF1a-MCS-3¢LTRDU3)
This work
pMF360 cPPT-RRE-SA was excised from pMF375 by SwaI/MluI and cloned into the corresponding sites
(SwaI/MluI) of pMF358
This work
pMF360x cPPT-RRE-SA was excised from pMF375 by SwaI/MluI and cloned into the corresponding sites
(SwaI/MluI) of pMF358x
This work
pMF363 PhCMV was excised from pLPCX using StuI/EcoRI and cloned into the compatible sites
(HpaI/EcoRI of pMF356 (5¢LTR-y+-oriSV40-cPPT-RRE-PhCMV-MCS-3¢LTRDU3)
This work
pMF365 EYFP was excised from pMF201 by EcoRV/SpeI and ligated to the compatible sites (SmaI/SpeI)
of pMF359 (5¢LTR-y+-oriSV40-cPPT-RRE-PhEF1a-EYFP-3¢LTRDU3)
This work
pMF371 ECFP was excised from pMF201 by EcoRI/NotI and ligated to the corresponding sites
(EcoRI/NotI) of pMF363 (5¢LTR-y+-oriSV40-cPPT-RRE-PhCMV-ECFP-3¢LTRDU3)
This work
pMF375 cPPT-RRE-SA was ampli®ed from pNL-EGFPDU3 using OMF191/OMF192 and cloned
into pcDNA3.1/V5-His TOPO
This work
pMF376 R-U5-y+-SD was ampli®ed from pNL-EGFPDU3 using OMF185/OMF193 and cloned
into pcDNA3.1/V5-His TOPO
This work
pMF378 OriSV40 was ampli®ed from pNL-EGFPDU3 using OMF195/OMF196 and cloned into
pcDNA3.1/V5-His TOPO
This work
pMF388 The 5¢LTR-y+-oriSV40-cPPT-RRE-MCS-3¢LTRDU3 was ampli®ed from pMF356 by
OMF199/OMF200 and cloned as AatII/NheI fragment to the compatible sites (AatII/XbaI) of the
pTRIDENT1 backbone (5¢LTR-y+-oriSV40-cPPT-RRE-MCS-3¢LTRDU3)
This work
pMF394 PhCMV-EYFP was excised from pMF351 using HpaI/KpnI and cloned into the corresponding
sites (HpaI/KpnI) of pMF388 (5¢LTR-y+-oriSV40-cPPT-RRE-PhCMV-EYFP-3¢LTRDU3)
This work
pMF402 PPT-3¢LTRDU3 was excised from pMF355 by MluI/XbaI and cloned into the corresponding
sites (MluI/XbaI) of pMF360
This work
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In vivo transduction of chicken embryos
Experiments on chicken embryos were conducted following
the shell-free cultivation protocols by Djonov and co-workers
(30). After 3 days of incubation at 37°C, Brown Leghorn eggs
were opened, and their contents were carefully poured into
plastic Petri dishes, 80 mm in diameter. The chicken embryos
were incubated at 37°C in a humidi®ed atmosphere.
Recombinant lentiviruses were applied locally on the top of
the growing chorioallontoic membrane (CAM) or injected
intravenously at embryonic day 9. On embryonic day 11, the
CAMs were examined by in vivo ¯uorescence microscopy
following intravenous (i.v.) injection of 0.1 ml 2.5 ¯uor-
esceine isothiocyanate dextran (2 000 000; Sigma, St Louis,
Table 1. Continued
Plasmid Description Reference or source
pBM1 The ECFP-IRESI-RFP cassette was excised from pWW85 by EcoRI/AscI and cloned into the
corresponding sites of pLentiTRIDENT2 (EcoRI/AscI) 5¢LTR-y+-oriSV40-cPPT-RRE-PhCMV-ECFP-
IRESI-RFP-IRESII-MCSIII-3¢LTRDU3
This work
pBM6 The PPGK-neo cassette was ampli®ed from pMSCVneo using OBM1/OBM2 and cloned in sense
orientation into pcDNA3.1/V5-His TOPO
This work
pMB7 PEF1a was excised from pMF320 using EcoRV/XmaI and cloned into the compatible sites
(HpaI/XmaI) of pMF388 (5¢LTR-y+-oriSV40-cPPT-RRE-PhEF1a-MCS-3¢LTRDU3)
This work
pBM8 The PPGK-neo cassette was excised from pBM6 by PacI/MluI and cloned into the corresponding sites
(PacI/MluI) of pMF356 (5¢LTR-y+-oriSV40-cPPT-RRE-MCSI-PPGK-neo-MCSII-3¢LTRDU3)
This work
pBM9 The PPGK-neo cassette was excised from pBM6 by PacI/MluI and inserted into the corresponding sites
(PacI/MluI) of pMF359 (5¢LTR-y+-oriSV40-cPPT-RRE-PEF1a-MCSI-PPGK-neo-MCSII-3¢LTRDU3)
This work
pBM13 The PPGK-neo cassette was excised from pBM6 using PacI/MluI and cloned into the corresponding sites
(PacI/MluI) of pMF388 (5¢LTR-y+-oriSV40-cPPT-RRE-MCSI-PPGK-neo-MCSII-3¢LTRDU3)
This work
pBM14 The PPGK-neo cassette was excised from pBM6 using PacI/MluI and cloned into the corresponding sites
(PacI/MluI) of pBM7 (5¢LTR-y+-oriSV40-cPPT-RRE-PEF1a-MCSI-PPGK-neo-MCSII-3¢LTRDU3)
This work
pBM40 EYFP was excised from pLentiModule4 by NheI/MluI and cloned into the compatible sites (SpeI/MluI)
of pBM7 (5¢LTR-y+-oriSV40-cPPT-RRE-PhEF1a-EYFP-3¢LTRDU3)
This work
pBM42 mEPO was excised from pMF242 by EcoRI/EcoRV and cloned into the compatible sites (EcoRI/PmeI)
of pMF359 (5¢LTR-y+-oriSV40-cPPT-RRE-PhEF1a-EPO-3¢LTRDU3)
This work
pBM43 VEGF121 was excised from pWW265 by SalI/MluI and ligated into the corresponding sites (SalI/MluI)
of pMF359 (5¢LTR-y+-oriSV40-cPPT-RRE-PhEF1a-VEGF121-3¢LTRDU3)
This work
pBM44 SEAP was excised from pSS173 by EcoRI/EcoRV and ligated into the compatible sites (EcoRI/PmeI)
of pMF359 (5¢LTR-y+-oriSV40-cPPT-RRE-PhEF1a-SEAP-3¢LTRDU3)
This work
pLentiTRIDENT1 The MCSI-IRESI-MCSII-IRESII-MCSIII cassette was excised from pTRIDENT1 by EcoRI/BglII and
cloned into the compatible sites (EcoRI/BamHI) of pMF363 (5¢LTR-y+-oriSV40-cPPT-RRE-PhCMV-MCSI-
IRESI-MCSII-IRESII-MCSIII-3¢LTRDU3) (pMF370)
This work
pLentiTRIDENT2 The MCSI-IRES-MCSII-CITE*-MCSII cassette was excised from pTRIDENT3 by EcoRI/BglII and
cloned into the compatible sites (EcoRI/BamHI) of pMF363 (5¢LTR-y+-oriSV40-cPPT-RRE-PhCMV-MCSI-
IRES-MCSII-CITE*-MCSIII-3¢LTRDU3) (pMF369)
This work
pLentiTFT1 The triple-¯uorescent expression cassette ECFP-IRESI-RFP-IRESII-EYFP was excised from pWW85
using EcoRI/MluI and cloned into the corresponding sites (EcoRI/MluI) of pLentiTRIDENT1
(5¢LTR-y+-oriSV40-cPPT-RRE-PhCMV-ECFP-IRESI-RFP-IRESII-EYFP-3¢LTRDU3) (pMB2)
This work
pLentiTFT2 EYFP was excised from pWW85 by SpeI/MluI and cloned to the corresponding sites (SpeI/MluI) of
pBM1 (5¢LTR-y+-oriSV40-cPPT-RRE-PhCMV-ECFP-IRES-RFP-CITE*-EYFP-3¢LTRDU3) (pMB3)
This work
pLentiModule1 PPT-3¢LTRDU3 was excised from pMF355 by MluI/XbaI and cloned into the corresponding sites
(MluI/XbaI) of pMF360x (XhoI/NruI-U31-StuI/SbfI-U32-SrfI-R-U5-y+-SD-SwaI-cPPT-RRE-SA-MCS-
DU31-PmeI/HpaI/BclI-DU32-NdeI/NheI/SalI/XbaI) (pBM4)
This work
pLentiModule2 The PhCMV-EYFP cassette was excised from pMF351 by EcoRI/MluI and cloned into the corresponding
sites (EcoRI/MluI) of pLentiModule1 (XhoI/NruI-U31-StuI/SbfI-U32-SrfI-R-U5-y+-SD-SwaI-cPPT-RRE-
SA-PhCMV-EYFP-DU31-PmeI/HpaI/BclI-DU32-NdeI/NheI/SalI/XbaI) (pBM5)
This work
pLentiModule3 oriSV40 was excised from pMF378 by XbaI/NheI and cloned into the XbaI sites of pLentiModule1
(XhoI/NruI-U31-StuI/SbfI-U32-SrfI-R-U5-y+-SD-SwaI-cPPT-RRE-SA-MCS-DU31-PmeI/HpaI/BclI-DU32-
NdeI/NheI/SalI/XbaI-oriSV40) (pBM15)
This work
pLentiModule4 oriSV40 was excised from pMF378 by XbaI/NheI and cloned into the XbaI sites of pLentiModule2
(XhoI/NruI-U31-StuI/SbfI-U32-SrfI-R-U5-y+-SD-SwaI-cPPT-RRE-SA-PhCMV-EYFP-DU31-PmeI/HpaI/BclI-
DU32-NdeI/NheI/SalI/XbaI-oriSV40) (pBM12)
This work
pLentiModule5 The PhEF1a-EYFP cassette was excised from pMF365 by BamHI and ligated in sense orientation into
the corresponding site (BamHI) of pLentiModule1 (XhoI/NruI-U31-StuI/SbfI-U32-SrfI-R-U5-y+-SD-SwaI-
cPPT-RRE-SA-PhEF1a-EYFP-DU31-PmeI/HpaI/BclI-DU32-NdeI/NheI/SalI/XbaI) (pBM45)
This work
pLentiModule6 The PhEF1a-VEGF121 cassette was excised from pBM43 by BamHI and ligated in sense oritentation into
the corresponding site (BamHI) of pLentiModule1 (XhoI/NruI-U31-StuI/SbfI-U32-SrfI-R-U5-y+-SD-SwaI-
cPPT-RRE-SA-PhEF1a-VEGF121-DU31-PmeI/HpaI/BclI-DU32-NdeI/NheI/SalI/XbaI) (pBM46)
This work
pLentiModule7 The PhEF1a-EPO cassette was excised from pBM42 by BamHI and ligated in sense orientation into the
corresponding site (BamHI) of pLentiModule1 (XhoI/NruI-U31-StuI/SbfI-U32-SrfI-R-U5-y+-SD-SwaI-cPPT-
RRE-SA-PhEF1a-EPO-DU31-PmeI/HpaI/BclI-DU32-NdeI/NheI/SalI/XbaI) (pBM47)
This work
pLentiModule8 The PhEF1a-SEAP cassette was excised from pBM44 by BamHI and ligated in sense orientation into the
corresponding site (BamHI) of pLentiModule1 (XhoI/NruI-U31-StuI/SbfI-U32-SrfI-R-U5-y+-SD-SwaI-
cPPT-RRE-SA-PhEF1a-SEAP-DU31-PmeI/HpaI/BclI-DU32-NdeI/NheI/SalI/XbaI) (pBM48)
This work
e113 Nucleic Acids Research, 2002, Vol. 30 No. 21 PAGE 4 OF 18
MO) (31). The developing blood vessels were monitored using
a Polyvar-Reichert ¯uorescent microscope at a magni®cation
of 253. The microscope was equipped with a custom-built
heating table to maintain the temperature of the specimens at
37°C. Blood circulation and microvascular patterns were
monitored for ~15 min for every CAM using an LE CCD
Optronics video camera (Visitron system, Puchheim,
Germany) and a digital video recorder (Sony, DHR-1000 VC).
Construction of lentiviral expression vectors
Lentiviral expression vectors (Table 1) containing extended
multiple cloning sites. The basic multi-purpose lentiviral
expression vector pMF356 (5¢LTR-y+-oriSV40-cPPT-RRE-
MCS-3¢LTRDU3) is derived from pNL-EGFPDU3, a pNL
series lentiviral vector containing an EcoRV/PvuII deletion in
the U3 region (corresponding to 8666±9066 in Genbank
accession no. AF033819) of the 3¢LTR [3¢LTRDU3 (25,32)].
pMF356 was constructed by a two-step procedure as
follows. (i) The PhCMV-EYFP cassette (PhCMV, promoter of
the human cytomegalovirus; EYFP) was ampli®ed from
pEYFP-C1 (Clontech, Palo Alto, CA) using oligonucleotides
OMF179: GATCGTTAACTCTAGAGGCGCGCCCGGGC-
GAATTCGTCGACCCGCGGCCTGCAGGCCGGCCATC-
GATCGCGAGCGGCCGCtagttattaatagtaatc [annealing
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sequence in lower case, restriction sites HpaI/HincII/XbaI/
AscI/SrfI/SmaI/EcoRI/SalI/SacII/SbfI/FseI/ClaI (GmATC sen-
sitive) /NruI/NotI are underlined] and OMF180: GATC-
GGTACCTCGAGGATCCGTTTAAACGCGTATTTAAA-
TTAATTAGCGATCGCACTAGTGCATGCTTCGAAGC-
GGCCGCttacttgtacagctcgtc (annealing sequence in lower
case, restriction sites KpnI/XhoI/BamHI/PmeI/MluI/SwaI/
PacI/SgfI/SpeI/SphI/SfuI/NotI are underlined) and ligated
as HpaI/KpnI fragment into pNL-EGFPDU3 resulting
in pMF351 (5¢LTR-y+-oriSV40-cPPT-RRE-MCSI-PhCMV-
EYFP-MCSII-3¢LTRDU3). (ii) The PhCMV-EYFP cassette was
eliminated from pMF351 by NotI restriction and religation,
which resulted in pMF356 (5¢LTR-y+-oriSV40-cPPT-RRE-
MCS-3¢LTRDU3).
pMF356 was further digested with PacI/MluI and the PacI/
MluI PPGK-neo (PPGK, promoter of the phosphoglycerate
Figure 1. (Previous page and above) SIN lentivectors containing optimized MCS. Generic HIV-1-derived lentivectors containing the 5¢LTR, the extended
packaging signal (y+), the Simian virus 40 origin of replication (oriSV40), the cPPT, the RRE and the 3¢LTR with deleted enhancer sequences (3¢LTRDU3).
The MCS was placed between RRE and 3¢LTRDU3. Besides this basic lentivector con®guration a variety of derivatives containing different mammalian/
human promoters (PPGK, phosphoglycerate kinase promoter; PhEF1a, human elongation factor 1a promoter; PhCMV, human immediate early cytomegalovirus
promoter) and reporter (EYFP and ECFP) or resistance genes (neo, G418 resistance gene) have been designed.
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kinase; neo, G418 resistance gene) cassette of pBM6 was
inserted (pBM8; 5¢LTR-y+-oriSV40-cPPT-RRE-MCSI-PPGK-
neo-MCSII-3¢LTRDU3). pBM6 was constructed by amplifying
PPGK-neo from pMSCVneo (Clontech) using oligonucleotides
OBM1: CGACTAGTTTAATTAAaattctaccgggtagggg (an-
nealing sequence in lower case, SpeI/PacI sites are under-
lined) and OBM2: CGGGTACCACGCGTcctcagaagaac-
tcgtcaag (annealing sequence in lower case, KpnI/MluI sites
are underlined) and cloned in sense orientation into
pcDNA3.1/V5-His TOPO (Invitrogen, Carlsbad, CA).
pMF356 derivatives containing either PhEF1a (PhEF1a,
promoter of the human elongation factor 1a; pMF359) or
PhCMV (pMF363) promoters were generated as follows.
pMF359 (5¢LTR-y+-oriSV40-cPPT-RRE-PhEF1a-MCS-
3¢LTRDU3). (i) PhEF1a was ampli®ed from pEF4/MycHisB
(Invitrogen) using oligonucleotides OMF164: GATC-
GGATCCtgcaaagatggataaagt (annealing sequence in lower
case, BamHI site is underlined) and OMF165: GATC-
AAGCTTTTAATTAAGCGATCGCGCCCGGGCGCGGC-
CGCaactagccagcttgggtc (annealing sequence in lower case,
HindIII/PacI/SgfI/SrfI/SmaI/NotI sites are underlined) and
cloned in antisense orientation into pcDNA3.1/V5-His TOPO
(Invitrogen) to result in pMF320. PhEF1a was excised from
pMF320 by EcoRV/XmaI and cloned into the compatible sites
(HpaI/XmaI) of pMF356 thereby resulting in pMF359
(5¢LTR-y+-oriSV40-cPPT-RRE-PhEF1a-MCS-3¢LTRDU3). (ii)
EYFP was excised from pMF201 (33) by EcoRV/SpeI and
cloned into the compatible sites (SmaI/SpeI) of pMF359 to
result in pMF365 (5¢LTR-y+-oriSV40-cPPT-RRE-PhEF1a-
EYFP-3¢LTRDU3). (iii) pMF359 was restricted using PacI/
MluI and the PPGK-neo cassette excised from pBM6 by PacI/
MluI was inserted (pBM9; 5¢LTR-y+-oriSV40-cPPT-RRE-
PhEF1a-MCSI-PPGK-neo-MCSII-3¢LTRDU3). pMF359 deriva-
tives include: (i) pBM42: pMF359 was restricted with EcoRI/
PmeI and EPO (erythropoietin) excised from pMF242 (33) by
EcoRI/EcoRV was inserted (5¢LTR-y+-oriSV40-cPPT-RRE-
PhEF1a-EPO-3¢LTRDU3). (ii) pBM43: pMF359 was restricted
with SalI/MluI and VEGF121 (variant 121 of the vascu-
lar endothelial growth factor) excised from pWW265
(C.Weber and A.Zisch, unpublished data) by SalI/MluI was
inserted (5¢LTR-y+-oriSV40-cPPT-RRE-PhEF1a-VEGF121-
3¢LTRDU3). (iii) pBM44: pMF359 was restricted with
EcoRI/PmeI and SEAP (human placental secreted alkaline
phosphatase) excised from pSS173 (34) by EcoRI/EcoRV
was inserted (5¢LTR-y+-oriSV40-cPPT-RRE-PhEF1a-SEAP-
3¢LTRDU3).
pMF363 (5¢LTR-y+-oriSV40-cPPT-RRE-PhCMV-MCS-
3¢LTRDU3): (i) PhCMV was excised from pLPCX (Clontech)
with StuI/EcoRI and ligated to the compatible HpaI/EcoRI
sites of pMF356 to result in pMF363 (5¢LTR-y+-oriSV40-
cPPT-RRE-PhCMV-MCS-3¢LTRDU3). (ii) ECFP was excised
from pMF201 (33) by EcoRI/NotI and ligated to the corres-
ponding sites (EcoRI/NotI) of pMF363 thereby resulting
in pMF371 (5¢LTR-y+-oriSV40-cPPT-RRE-PhCMV-ECFP-
3¢LTRDU3).
Tricistronic pLentiTRIDENT expression vectors. pLenti-
TRIDENT vectors contain a pTRIDENT-derived tricistronic
expression cassette inserted in the MCS of pMF363.
pLentiTRIDENT1 (pMF370; 5¢LTR-y+-oriSV40-cPPT-RRE-
PhCMV-MCSI-IRESI-MCSII-IRESII-MCSIII-3¢LTRDU3) was
constructed by excising the MCSI-IRESI-MCSII-IRESII-
MCSIII cassette from pTRIDENT1 [pMF125 (35)] by
EcoRI/BglII and cloning it into the compatible sites (EcoRI/
BamHI) of pMF363. pLentiTRIDENT1 was further restricted
using EcoRI/MluI and the triple-¯uorescent expression
cassette (ECFP-IRESI-RFP-IRESII-EYFP) excised from
pWW85 (36) by EcoRI/MluI was inserted [pLentiTFT1
(pBM2); 5¢LTR-y+-oriSV40-cPPT-RRE-PhCMV-ECFP-IRESI-
RFP-IRESII-EYFP-3¢LTRDU3]. pLentiTRIDENT2 (pMF369;
5¢LTR-y+-oriSV40-cPPT-RRE-PhCMV-MCSI-IRES-MCSII-
CITE*-MCSIII-3¢LTRDU3) was constructed by excising
the MCSI-IRES-MCSII-CITE*-MCSIII cassette from
pTRIDENT3 [pMF122 (35)] by EcoRI/BglII and cloning it
into the compatible sites (EcoRI/BamHI) of pMF363.
pLentiTRIDENT2 was further restricted using EcoRI/AscI
and the ECFP-IRESI-RFP cassette excised from pWW85 (36)
by EcoRI/AscI was inserted to result in pBM1 (5¢LTR-y+-
oriSV40-cPPT-RRE-PhCMV-ECFP-IRES-RFP-CITE*-MCSIII-
3¢LTRDU3). Subsequently, pBM1 was digested using
SpeI/MluI and the EYFP cassette excised from pWW85 by
SpeI/MluI was inserted [pLentiTFT2 (pBM3); 5¢LTR-y+-
oriSV40-cPPT-RRE-PhCMV-ECFP-IRES-RFP-CITE*-EYFP-
3¢LTRDU3].
Highly compact lentiviral expression vectors. pNL-derived
lentiviral expression vectors contain super¯uous chromosomal
sequences ¯anking the lentiviral expression unit (32). In order
to eliminate these chromosomal sequences, the 5¢LTR-y+-
oriSV40-cPPT-RRE-MCS-3¢LTRDU3 cassette was ampli®ed
from pMF356 using oligonucleotides OMF199:
GATCGACGTCacttacaccaggaaaggc (annealing sequence in
lower case, AatII site is underlined) and OMF200:
GATCGCTAGCacctctacctcctggggg (annealing sequence in
lower case, NheI site is underlined) and cloned as AatII/NheI
fragment to the compatible, AatII/XbaI-restricted
pTRIDENT1 [pMF125 (35)] backbone thereby resulting in
pMF388 (5¢LTR-y+-oriSV40-cPPT-RRE-MCS-3¢LTRDU3).
pMF388 derivatives include: (i) pMF394: pMF388 was
restricted with HpaI/KpnI and the PhCMV-EYFP cassette
excised from pMF351 by HpaI/KpnI was inserted (5¢LTR-
y+-oriSV40-cPPT-RRE-PhCMV-EYFP-3¢LTRDU3). (ii) pBM7:
PhEF1a was excised from pMF320 by EcoRV/XmaI and cloned
into the compatible HpaI/XmaI sites of pMF388 (5¢LTR-y+-
oriSV40-cPPT-RRE-PEF1a-MCS-3¢LTRDU3). (iii) pBM13:
pMF388 was restricted with PacI/MluI and the PacI/MluI
PPGK-neo cassette excised from pBM6 was inserted (5¢LTR-
y+-oriSV40-cPPT-RRE-MCSI-PPGK-neo-MCSII-3¢LTRDU3).
(iv) pBM14: pBM7 was restricted with PacI/MluI and
the PacI/MluI PPGK-neo cassette excised from pBM6 was
inserted (5¢LTR-y+-oriSV40-cPPT-RRE-PEF1a-MCSI-PPGK-
neo-MCSII-3¢LTRDU3). (v) pBM40: pBM7 was restricted
with SpeI/MluI and EYFP excised from pBM12 by NheI/MluI
was inserted (5¢LTR-y+-oriSV40-cPPT-RRE-PhEF1a-EYFP-
3¢LTRDU3).
pLentiModule, a modular lentiviral expression vector (all sites
indicated correspond to GenBank accession no. AF033819).
pLentiModule consists of four minimal lentiviral modules
[U3, R-U5-y+-SD, cPPT-RRE-SA, PPT-3¢LTRDU3 (DU3-R-
U5)] containing unique restriction sites at their joints. These
modules were independently ampli®ed from pNL-EGFPDU3
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and cloned into pcDNA3.1/V5-His TOPO (Invitrogen). (i)
pMF352: U3 (8631±9085) was ampli®ed using oligonucle-
otides OMF183, GATCCTCGAGTCGCGActggaagggctaatttgg
(annealing sequence lower case, XhoI/NruI sites are under-
lined); and OMF184, GATCGCCCGGGCCAGTACAGGC-
AAAAAGCAGCTGCTTATATGTAGCATCTGAG-
GGCTCGCCACTCCCCAGTCCCGCCCAGGCCACACCT-
CCCTGCAGGcctggaaagtccccagcg (annealing sequence
lower case, SrfI and SbfI are underlined; this primer inserts a
SbfI at position 9007 of U3) (XhoI/NruI-U31-SbfI-U32-SrfI).
(ii) pMF376: R-U5-y+-SD (1±793) was ampli®ed from pNL-
EGFPDU3 using oligonucleotides OMF185, GATCGCC-
CGGGCggtctctctggttagacc (annealing sequence lower case,
SrfI site is underlined); and OMF193, GATCATT-
TAAATtttaaagttctaggtgat (annealing sequence lower case,
SwaI site is underlined) (SrfI-R-U5-y+-SD-SwaI). pMF353: a
shorter R-U5-y+-SD module (1±377) was ampli®ed using
oligos OMF185 and OMF186: GATCATTTAAAT-
tcattaatctaattctcc (annealing sequence lower case, SwaI site
is underlined). (iii) pMF375: cPPT-RRE-SA [4330±4475
(cPPT), 7200±8024 (RRE)] was ampli®ed using oligonucle-
otides OMF191, GATCATTTAAATatgcataaaagaaaaggg (an-
nealing sequence lower case, SwaI site is underlined); and
OMF192, CTAGGATCACGCGTTTAATTAAGCGATCG-
CACTAGTATCGATGGCGCGCCGGCCGGCCAGGCCT-
GCGGCCGCGAATTCGACGTCatccgttcactaatcgaa (anneal-
ing sequence lower case, MluI/PacI/SgfI/SpeI/ClaI/AscI/FseI/
StuI/NotI/EcoRI/AatII are underlined) (SwaI-cPPT-RRE-SA-
MluI /PacI /SgfI /SpeI /ClaI/AscI/FseI/StuI/NotI/EcoRI/AatII).
(iv) pMF355: PPT-3¢LTRDU3 (DU3-R-U5) (8615±9181 and
1±181) was ampli®ed using oligonucleotides OMF189,
GATCACGCGTGGATCCAAAAGAAAAGGGGGGACT-
GGAAGGGCTAATTCACTCCCAAAGAAGACAAGATG-
TTTAAACGTTAACTGATCActgctttttgcctgtact [annealing
sequence lower case, MluI/BamHI is underlined, PPT is
shown in bold; PmeI/HpaI/BclI are underlined and placed
between the EcoRV/PvuII (GAT ¼ CTG, italics) ligation
sites ¯anking the DU3 deletion (corresponding to 8666±9066)
of the 3¢LTR (25,32)]; and OMF190, GATCTCTAG-
AGTCGACGCTAGCCATATGctgctagagattttccaca (anneal-
ing sequence lower case, XbaI/SalI/NheI/NdeI are underlined)
(MluI/BamHI-PPT-DU31-PmeI/HpaI/BclI-DU32-R-U5-NdeI/
NheI/SalI/XbaI).
pLentiModule was assembled on a pTRIDENT1 backbone
following a four-step procedure. (i) U3 was excised from
pMF352 using XhoI/SrfI and ligated to the corresponding sites
(XhoI/SrfI) of pTRIDENT1 to result in pMF357. (ii) R-U5-
y+-SD was excised from pMF353 and pMF376 by SrfI/SwaI
and ligated into the corresponding sites (SrfI/SwaI) of pMF357
to result in pMF358 and pMF358x. (iii) cPPT-RRE-SA was
excised from pMF375 using SwaI/MluI and ligated into the
corresponding sites (SwaI/MluI) of pMF358 and pMF358x to
result in pMF360 and pMF360x. (iv) PPT-3¢LTRDU3 was
excised from pMF355 by MluI/XbaI and ligated into the
corresponding sites (MluI/XbaI) of pMF360 and pMF360x to
result in pMF402 and pLentiModule1 (pBM4; XhoI/NruI-
U31-StuI / SbfI-U32-SrfI-R-U5-y + -SD-SwaI-cPPT-RRE-SA-
AatII/EcoRI/NotI/EagI/StuI/FseI/EagI/AscI/BssHII/ClaI/SpeI/
SgfI/PacI/MluI/BamHI-DU31-PmeI/HpaI/BclI-DU32-NdeI/NheI/
SalI/XbaI). plentiModule1 derivatives include the following.
(i) pLentiModule2: pLentiModule1 was cut with EcoRI/MluI
Table 2. EPO, VEGF121 and SEAP production in CHO-K1 cells following
lentiviral transduction
Lentivector Production (ng/ml)
EPO VEGF121 SEAP
pBM42 65.4 6 9.2
pBM43 20.0 6 0.5
pBM44 2.1 3 103 6 80.6
pLentiModule7 37.1 6 5.5
pLentiModule6 11.3 6 1.1
pLentiModule8 1.1 3 103 6 23.6
Figure 2. Confocal microscopy analysis of transduction ef®ciencies of key
lentivectors. CHO-K1 were transduced with 2 3 106 EYFP-encoding
pMF365-, pBM40- and pLentiModule-derived lentiviruses. Transduced cells
were stained with the DNA-speci®c DRAQ5 dye and analyzed for YFP-
and DRAQ5-mediated ¯uorescence by confocal microscopy (magni®cation
2003).
Table 3. Titer and p24 production of various lentivectors
Lentivector Titer (c.f.u./ml)a p24 (ng/ml)
pNL-EGFPb 2 3 107 95.0 6 5.3
pNL-EGFPDU3 4 3 107 165.3 6 5.1
pMF351 2.5 3 107 104.8 6 6.4
pMF365 2 3 107 97.3 6 8.5
pBM2 ND 158.7 6 7.3
pBM40 2 3 107 97.3 6 9.6
pBM42 ND 66.1 6 8.3
pBM43 ND 70.6 6 7.8
pBM44 ND 63.5 6 8.0
pLentiModule1 2.5 3 107 110 6 7.2
pLentiModule2 2.5 3 107 110 6 7.3
pLentiModule4 2 3 107 97.2 6 12.3
pLentiModule5 1.2 3 107 48.6 6 5.4
pLentiModule6 ND 64.9 6 6.7
pLentiModule7 ND 58.8 6 8.6
pLentiModule8 ND 72.3 6 8.1
ND, not determined.
aDetermined as described in Reiser et al. (17).
bDetermined on NIH/3T3 cells, see Reiser et al. (17).
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and the PhCMV-EYFP cassette excised from pMF351 by
EcoRI/MluI was inserted to result in pLentiModule2
(pBM5) (XhoI/NruI-U31-StuI/SbfI-U32-SrfI-R-U5-y+-SD-
SwaI-cPPT-RRE-SA-PhCMV-EYFP-DU31-PmeI/HpaI/BclI-
DU32-NdeI/NheI/SalI/XbaI). (ii) pLentiModule5: pLenti-
Module1 was cut with BamHI and the PhEF1a-EYFP-encoding
BamHI cassette of pMF365 was inserted (pBM45) (XhoI/
NruI -U31-StuI/SbfI-U32-SrfI-R-U5-y+-SD-SwaI-cPPT-
RRE-SA-PhEF1a -EYFP-DU31-PmeI/HpaI/BclI-DU32-NdeI/
NheI/SalI/XbaI). (iii) pLentiModule6: pLentiModule1 was cut
with BamHI and the PhEF1a-VEGF121-encoding BamHI cas-
sette of pBM43 was inserted (pBM46) (XhoI/NruI-U31-StuI/
SbfI-U32-SrfI-R-U5-y+-SD-SwaI-cPPT-RRE-SA-PhEF1a-
VEGF121-DU31-PmeI/HpaI/BclI-DU32-NdeI/NheI/SalI/XbaI).
(iv) pLentiModule7: pLentiModule1 was cut with BamHI and
the PhEF1a-EPO-encoding BamHI cassette of pBM42 was
inserted (pBM47) (XhoI/NruI-U31-StuI/SbfI-U32-SrfI-R-U5-
y+-SD-SwaI-cPPT-RRE-SA-PhEF1a-EPO-DU31-PmeI/HpaI/
BclI-DU32-NdeI/NheI/SalI/XbaI). (v) pLentiModule8:
pLentiModule1 was cut with BamHI and the PhEF1a-SEAP-
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encoding BamHI cassette of pBM44 was inserted (pBM48)
XhoI/NruI-U31-StuI/SbfI-U32-SrfI-R-U5-y+-SD-SwaI-cPPT-
RRE-SA-PhEF1a-SEAP-DU31-PmeI/HpaI/BclI-DU32-NdeI/
NheI/SalI/XbaI).
In order to place the oriSV40 on pLentiModule1, this plasmid
was restricted with XbaI and the oriSV40 XbaI/NheI fragment
excised from pMF378 was inserted to result in pLentiModule3
(pBM15) (XhoI/NruI-U31-StuI/SbfI-U32-SrfI-R-U5-y+-SD-
SwaI-cPPT-RRE-SA-MCS-DU31-PmeI /HpaI /BclI -DU32-
NdeI/NheI/SalI/XbaI-oriSV40). pMF378 was constructed by
amplifying oriSV40 from pNL-EGFPDU3 using oligonucle-
otides OMF195: GATCTCTAGAtatgactccgcccatccc (anneal-
ing sequence lower case, XbaI site is underlined) and
OMF196: GATCGCTAGCttgcaaaagcctaggcc (annealing
sequence lower case, NheI sequence is underlined) and
ligating it into pcDNA3.1/V5-His TOPO. Furthermore,
pLentiModule2 was restricted with XbaI and the oriSV40
XbaI/NheI fragment excised from pMF378 was inserted to
result in pLentiModule4 (pBM12) (XhoI/NruI-U31-StuI/SbfI-
U32-SrfI -R-U5-y+-SD-SwaI-cPPT-RRE-SA-PhCMV-EYFP-
DU31-PmeI/HpaI/BclI-DU32-NdeI/NheI/SalI/XbaI-oriSV40).
Lentivirus production and infection
For production of replication-incompetent SIN lentiviruses, a
mixture containing 94 ml DMEM, 6 ml FUGENE (Roche
Diagnostics AG, Rotkreuz, Switzerland), 25 mM chloroquine,
1 mg pLTR-G [encoding the pseudotyping envelope protein
VSV-G of the vesicular stomatitis virus (17)], 1 mg of the
helper construct pCD/NL-BH* (32) and 1 ml of the desired
transgene-encoding lentiviral expression vector were trans-
fected into human embryonic kidney cells (HEK293-T, kindly
provided by Andreas Zisch). The medium was replaced after
12±15 h and virus particles were produced for another 48 h.
Viral particles were collected from the HEK293-T supernatant
by ®ltration through a 0.45 mm ®lter (Schleicher & Schuell
GmbH, Dassel, Germany: FP 030/2) yielding typical titers of
2 3 107 c.f.u./ml when titrated on CHO-K1 cells. p24 assays
were performed using a commercial kit (NEK-050, Perkin
Elmer, Boston, MA) [pMF351, 104.8 6 6.4 ng/ml p24;
pLentiModule1, 109.9 6 7.25 ng/ml p24 (triplicate mean
values)]. 60 000 target cells per 6-well were infected with
200 ml viral supernatant. Hippocampal slice cultures were
infected as described by Ehrengruber and co-workers (37).
RESULTS
Design of multi-purpose lentiviral expression vectors
containing extensive multiple cloning sites
Most lentiviral expression vectors currently available from the
research groups, which have pioneered lentiviral transduction
technologies are lacking extensive MCS rendering the
straightforward design of HIV-1-based expression vectors
complicated (16). We have constructed a versatile lentiviral
expression vector family derived from the HIV-1-based SIN
pNL-EGFPDU3 (J.Reiser, unpublished data; 38) which con-
tains up to 29 unique sites for restriction endonucleases, many
of which are rare-cutting 8 bp-recognizing enzymes. pNL-
EGFPDU3 has a classical lentiviral expression vector set-up
Figure 3. (Previous page and above) Size-optimized SIN lentivectors. These lentivectors are derivatives of the ones shown in Figure 1 and are devoid of any
chromosomal sequences ¯anking the lentiviral expression vectors.
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consisting of 5¢LTR, y+, splice donor (SD), origin of
replication of the simian virus 40 (oriSV40), central polypurine
tract (cPPT), RRE, splice acceptor (SA) and a 3¢LTRDU3. The
PhCMV-EGFP expression cassette is inserted between the SA
and the 3¢LTRDU3 using the unique HpaI and KpnI sites
(5¢LTR-y+-SD-oriSV40-cPPT-RRE-SA-HpaI-PhCMV-EGFP-
KpnI-3¢LTRDU3). The oriSV40 is boosting the vector copy
number in transiently transfected cells producing SV40 large
T antigen, such as HEK293-T cells (17). A 400 bp EcoRV/
PvuII deletion within the 3¢LTR (3¢LTRDU3) inactivates the
5¢LTR promoter upon reverse transcription and integration
when the DU3 deletion is transferred to the 5¢LTR in a self-
suf®cient manner, a process also referred to as SIN (25,26).
In order to extend the MCS of pNL-EGFPDU3, a PCR-
ampli®ed PhCMV-EYFP cassette ¯anked by 26 unique restric-
tion sites was cloned into the HpaI/KpnI sites of
pNL-EGFPDU3 and resulted in pMF351 (5¢LTR-y+-oriSV40-
cPPT-RRE-MCSI-PhCMV-EYFP-MCSII-3¢LTRDU3; Fig. 1,
Table 1). The PhCMV-EYFP was subsequently excised by a
NotI deletion resulting in pMF356, a lentiviral expression
vector containing 28 unique restriction sites (5¢LTR-y+-
oriSV40-cPPT-RRE-MCS-3¢LTRDU3; Fig. 1, Table 1). As non-
exhaustive examples for the construction kit-like lentiviral
expression vector platform a variety of pMF356 derivatives
have been designed which contain: (i) a PPGK-driven
neomycin resistance gene (neo) (pBM8; 5¢LTR-y+-oriSV40-
cPPT-RRE-MCSI-PPGK-neo-MCSII-3¢LTRDU3), (ii) a
strong constitutive human elongation factor 1a promoter
(PhEF1a; pMF359; 5¢LTR-y+-oriSV40-cPPT-RRE-PhEF1a-
MCS-3¢LTRDU3), (iii) a PhEF1a-driven EYFP cassette
(pMF365; 5¢LTR-y+-oriSV40-cPPT-RRE-PhEF1a-MCSI-
EYFP-MCSII-3¢LTRDU3), (iv) a PhEF1a promoter plus a
PPGK-neo cassette (pBM9; 5¢LTR-y+-oriSV40-cPPT-RRE-
PhEF1a-MCSI-PPGK-neo-MCSII-3¢LTRDU3), (v) a human cy-
tomegalovirus immediate early promoter (PhCMV; pMF363;
5¢LTR-y+-oriSV40-cPPT-RRE-PhCMV-MCS-3¢LTRDU3) or
(vi) a PhCMV-ECFP cassette (pMF371; 5¢LTR-y+-oriSV40-
cPPT-RRE-PhCMV-MCSI-ECFP-MCSII-3¢LTRDU3) (see Fig. 1
and Table 1 for all plasmids).
In order to validate this class of multi-purpose lentivectors,
a variety of pMF359 derivatives were constructed which
encode EPO (pBM42), the vascular endothelial growth factor
(VEGF121, pBM43) or the SEAP (pBM44) under control of
PhEF1a. pBM42-, pBM43- and pBM44-derived lentiviruses
were able to drive high-level protein secretion following
transduction of CHO-K1 (Table 2). Also, pMF351- and
pMF365-based lentivectors displayed similar transduction
ef®ciencies compared with their parental constructs of the
pNL-EGFP series (38) (Fig. 2, Table 3).
Although the basic lentiviral expression units contained in
these expression vectors (pMF351, pMF356, pBM8, pMF359,
pMF365, pBM9, pBM363, pMF371; Fig. 1) are only ~3.5 kb
in size, they are ¯anked by super¯uous chromosomal regions
that are remnants of the integration sites of the ®rst HIV
proviruses cloned from the human chromosome [molecular
clone HXB2 (39)]. As these chromosomal sites are not
packaged and transferred to the target cells, they are not
limiting the cargo size of the lentiviral expression units.
However, the entire expression vectors may reach the
replicative limit when ampli®ed in Escherichia coli.
Elimination of any chromosomal sequences was achieved
by PCR-mediated ampli®cation of the lentiviral expression
units (5¢LTR-y+-oriSV40-cPPT-RRE-MCS-3¢LTRDU3). AatII
and NheI sites engineered in the primer extensions enabled
ligation to the pTRIDENT-derived minimal high-copy num-
ber vector backbone fragment generated by AatII/XbaI
digestion (35,40). This cloning procedure resulted in
pMF388, a 4.8 kb vector containing a lentiviral expression
module with 29 unique restriction sites for convenient
integration of desired transgenes (Fig. 3, Table 1; pMF388,
5¢LTR-y+-oriSV40-cPPT-RRE-MCS-3¢LTRDU3). Several ex-
emplary pMF388 derivatives have been designed which
contain in addition to the basic lentiviral expression unit: (i)
a PhCMV-driven EYFP cassette (pMF394; 5¢LTR-y+-oriSV40-
cPPT-RRE-MCSI-PhCMV-EYFP-MCSII-3¢LTRDU3), (ii) a
PhEF1a promoter (pBM7; 5¢LTR-y+-oriSV40-cPPT-RRE-
PhEF1a-MCS-3¢LTRDU3), (iii) a PhEF1a-driven EYFP cas-
sette (pBM40; 5¢LTR-y+-oriSV40-cPPT-RRE-PhEF1a-EYFP-
Figure 4. Transduction of optimized lentivectors into various insect,
chicken, murine and human cell types as exempli®ed by VSV-G-pseudo-
typed pMF351-derived lentiviruses (Fig. 1). The gene encoding the EYFP
was successfully transduced into Chinese hamster ovary cells (CHO-K1),
baby hamster kidney cells (BHK-21), human ®brosarcoma cells (HT-1080),
human cervial adenocarcinoma cells (HeLa), human hepatocellular
carcinoma cells (HepG2), human chronic myelogenous leukemia cells
(K-562), bursal chicken cells (DT40) as well as insect cells (SF9). pMF351-
derived lentiviruses also transduced glial cells in hippocampal slice cultures
(hippocampal slice) and primary ARC (magni®cation 1003, hippocampal
slice 503; ARC 4003).
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3¢LTRDU3), (iv) a PPGK-driven neomycin resistance cassette
(PPGK-neo; pBM13; 5¢LTR-y+-oriSV40-cPPT-RRE-MCSI-
PPGK-neo-MCSII-3¢LTRDU3) or (v) a PhEF1a promoter plus a
PPGK-neo cassette (pBM14; 5¢LTR-y+-oriSV40-cPPT-RRE-
PhEF1a-MCSI-PPGK-neo-MCSII-3¢LTRDU3) (see Fig. 3 and
Table 1 for all plasmids).
Besides the great ¯exibility to accommodate almost any
desired transgene, the extended MCS of the lentiviral expres-
sion vectors shown in Figures 1 and 3 are fully compatible
with pQuattro, pTRIDENT, pRetroTRIDENT, pTWIN,
pRetroTWIN and pDuoRex type constructs and enable one-
step exchange of multicistronic and regulated expression units
among these different expression vector families (35,40±42).
In addition, these vectors facilitate straightforward swapping
of cis-acting elements and transgene expression units between
each other using: (i) remaining polylinker sites; (ii) unique
restriction sites within the (5¢) b-lactamase coding region (bla;
AseI, FspI, XmnI, SspI, AatII); and/or (iii) corresponding cis-
acting elements (EcoRV, NarI, BssHII, XmnI, S®I, StuI, NsiI).
We have tested the construction kit-like lentiviral expres-
sion vector platform by infecting various insect (SF9), chicken
(DT40), murine (BHK-21, CHO-K1) and human (HeLa, HT-
1080, HepG2, K-562) cell lines as well as ARC and
hippocampal slices using the pMF351-derived lentivirus
(5¢LTR-y+-oriSV40-cPPT-RRE-MCS-PhCMV-EYFP-MCSII-
3¢LTRDU3). All cell lines transduced with pMF351-derived
lentiviruses show high-level expression of the EYFP while
EYFP expression is absent in mock-transduced control
cultures. Even ARCs, which are known to be refractory to a
variety of transfection/transduction technologies, were readily
transduced by the pMF351-derived lentivirus providing an
alternative to the recently described Sindbis-based transduc-
tion systems (28). Also, this lentivirus transduced glial cells in
rat hippocampal slices (Fig. 4). In CHO-K1 cells the
transduction ef®ciency of pBM4-derived lentiviruses was
similar compared with the parental pNL-EGFP and pMF351
vector series (38) (see above and Fig. 2, Table 3).
The biological potential of lentiviral transduction was
further exempli®ed by expression of VEGF in chicken
embryos. Infection of the chick embryos' CAM with increas-
ing concentrations of pBM43-derived lentiviruses (5¢LTR-
y+-oriSV40-cPPT-RRE-PhEF1a-VEGF121-3¢LTRDU3) resulted
in a dose-dependent VEGF121-mediated local induction of
new blood vessels demonstrated by increased vascular dens-
ity, enhanced formation of numerous arterioles and venules as
well as by a boost in vessel endpoint and branching density
(Fig. 5). When overdosing VEGF121 (5 3 106 c.f.u./ml
producing 35.5 6 3.8 ng/ml VEGF121 in 48 h; not shown) or
following i.v. application of pBM43-derived lentivirus (1.5 3
106 c.f.u./ml producing 10.6 6 0.9 ng/ml VEGF121 in 48 h),
the hierarchical, tree-like structure of the supplying vessels
disappears and the multitude of arterioles and venules adopt an
irregular tortuous shape associated with atypical delta- or
brush-like vessel endpoints (Fig. 5D).
Construction of pLentiTRIDENT vectors for tricistronic
expression of up to three transgenes
Multicistronic expression technologies for coordinated
expression of several transgenes from a single arti®cial
eukaryotic operon have generated unprecedented impact in
Figure 5. In vivo examination of microvascular growth in the CAM of 11 day old chicken embryos 48 h after pBM43-based lentiviral VEGF121 transduction.
Whereas the regular vessel pattern observed on the CAM remained intact in mock transductions (A), dose-dependent angiogenic response resulted in increased
vascular density and atypical (brush- and delta-like) endpoint patterns following spotting of 0.5 3 106 c.f.u./ml (producing 3.4 6 0.3 ng/ml VEFF121 in 48 h)
(B), 3 3 106 c.f.u./ml (producing 21.2 6 1.7 ng/ml VEGF121 in 48 h) or i.v. injection of 1.5 3 106 c.f.u./ml (producing 10.6 6 0.9 ng/ml VEGF121 in 48 h)
(C) (magni®cation 253).
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rational reprogramming of mammalian production cell lines
and anti-in¯ammation engineering (43,44). Particularly in a
therapeutic setting when the therapeutic proteins consist of
multiple subunits or multiple target/strategy approaches
involving ribozymes, antisense RNA, transdominant pro-
teins and intracellular antibodies, multicistronic expression
technologies are highly desirable (45). We have recently
pioneered a multicistronic expression vector family,
pTRIDENT, which enables tricistronic expression of up to
three transgenes from a single constitutive or regulatable
promoter. Whereas the ®rst cistron is translated in a classical
cap-dependent manner, translation initiation of the second and
third cistrons rely on viral cap-independent internal ribosome
entry sites of poliovirus (IRES) or encephalomyocarditis virus
Figure 6. pLentiTRIDENT, tricistronic lentiviral expression vectors for simultaneous expression of up to three transgenes. Besides the basic lentiviral cis-act-
ing elements (see Fig. 1) pLentiTRIDENT contain a tricistonic expression unit consisting of two IRES or encephalomyocarditis viral origin (CITE*) ¯anked
by extensive MCS for integration of desired transgenes, for example the ones encoding the cyan (ECFP), red (RFP) and yellow (EYFP) ¯uorescent genes
(pLentiTFT1 and pLentiTFT2).
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(CITE) which had been optimized for maximum translation
enhancement (CITE*) (35,40,42).
In order to merge multicistronic expression and lentiviral
transduction technology, we have designed the pLenti-
TRIDENT vector series, which contains a PhCMV-driven
tricistronic eukaryotic operon within a pMF356-derived
lentiviral expression cassette (Fig. 6, Table 1). pLenti-
TRIDENT1/(pLentiTRIDENT2) was constructed by excising
the MCSI-IRESI-MCSII-IRESII/(CITE*)-MCSIII cassette of
pTRIDENT1/(pTRIDENT3) by EcoRI/BglII and ligating
it into the lentiviral transduction unit of pMF363 (EcoRI/
BamHI) [5¢LTR-y+-oriSV40-cPPT-RRE-PhCMV-MCSI-IRESI-
MCSII-IRESII/(CITE*)-MCSIII-3¢LTRDU3]. The pLenti-
TRIDENT vectors were validated by inserting the genes
encoding the (enhanced) cyan, red and yellow ¯uorescent
proteins into the ®rst, second and third cistrons, respectively,
which resulted in the triple-¯uorescent pLentiTRIDENT
vectors (pLentiTFT1/(pLentiTFT2). CHO-K1 cells and glial
cells in hippocampal slices transduced with pLentiTFT
vectors showed simultaneous high-level expression of all
three ¯uorescent marker proteins (Fig. 7).
pLentiModule, an advanced highly modular lentiviral
expression system
Previous lentiviral expression vectors have been designed for
optimal integration of desired transgenes by engineering of
extended MCS. However, lentiviral transduction units have
been successfully modi®ed in the past years to optimize
speci®c cis-acting modules for: (i) Tat-independent produc-
tion of lentiviruses by replacement of the 5¢LTR enhancer
region (19,23,26,46); (ii) optimization of packaging signal and
Rev-responsive elements (47,48); and (iii) replacement of the
enhancer sequences of the 3¢LTR by LoxP sequences for
conditional site-speci®c excision of transduced expression
units (49) or by antibiotic-responsive operator modules for
conditional proviral gene expression (46).
In order to combine minimal lentiviral transduction mod-
ules with extended polylinkers and the highest ¯exibility for
advanced modi®cation of the cis-acting elements we designed
a novel modular lentivector (pLentiModule) which consists of
four modules: (i) XhoI/NruI-U31-StuI/SbfI/PstI-U32-SrfI, (ii)
SrfI-R-U5-y+-SD-SwaI/NsiI, (iii) SwaI/NsiI-cPPT-RRE-SA-
MCSI and (iv) MCSI-3¢LTRDU3(1)-MCSII-3¢LTRDU3(2)-
MCSIII. These modules are ¯anked by unique restriction
sites and were sequentially assembled into a minimal
pTRIDENT-derived prokaryotic vector backbone to result in
pLentiModule1 [XhoI/NruI-U31-StuI/SbfI/PstI-U32-SrfI-R-
U5-y+-SD-SwaI/NsiI -cPPT-RRE-SA-MCSI-3¢LTRDU3(1)-
MCSII-3¢LTRDU3(2)-MCSIII; Fig. 8, Table 1]. In contrast to
the previously described lentivectors pLentiModule is devoid
of the oriSV40 since transfer of this simian virus element into
target cells is incompatible with current therapeutic mod-
alities.
pLentiModule1 displays a construction kit-like highly
modular structure and enables design of the following
lentivector characteristics. (i) Transfer of the entire lentiviral
expression cassette using the ¯anking unique sites XhoI/NruI
and MCSIII, (ii) exchange of the 5¢U3 region by XhoI/NruI
and SrfI, (iii) switching of the 5¢U3 enhancer (Tat-binding)
sequences by XhoI/NruI and StuI/SbfI/PstI, (iv) substitution of
the R-U5-y+-SD module using SrfI and SwaI/NsiI, (v)
replacement of the cPPT-RRE-SA module by modi®ed
counterparts using the SwaI/NsiI and MCSI sites, (vi) cloning
of desired transgenes, promoters and resistance cassettes into
MCSI which is also compatible with the pLentiTRIDENT
vectors and all of the previously described lentivectors (Figs 1,
3 and 6), (vii) swapping of the 3¢LTRDU3 element using sites
contained in MCSI and MCSIII and (viii) integration of
functional units (for example, LoxP, tissue-speci®c or
regulatable operators, insulator sequences) into MCSII
which are copied into the 5¢LTR upon reverse transcription
and integration. In addition, (ix) cassette swapping with all
other vectors described here is further facilitated using any of
the sites within the bla region (AseI/FspI/XmnI/SspI/AatII) and
the R-U5-y+-SD module (NarI/BssHII/XmnI).
pLentiModule1 was tested by insertion of a PhCMV-EYFP
cassette into its MCS (pLentiModule2; Fig. 6, Table 1) and
transduction into insect (SF9), chicken (DT40), murine (BHK-
21, CHO-K1) and human (HeLa, HT-1080, HepG2, K-562)
cell lines as well as into ARCs and glial cells of hippocampal
slice cultures (Fig. 9). Furthermore, pLentiModule1-derived
lentivectors encoding EPO (pLentiModule7), VEGF121
(pLentiModule6) or SEAP (pLentiModule8) under control
Figure 7. Transduction of Chinese hamster ovary (CHO-K1) cell and glial cells in rat hippocampal slice cultures using pLentiTRIDENT1-derived lentiviruses.
Simultanous expression of the genes encoding the cyan, red and yellow ¯uorescent proteins could be observed (magni®cation 2003).
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PhEF1a display high-level expression of these therapeutic/
reporter proteins in CHO-K1 cells (Tables 2 and 3).
As pLentiModule1 and pLentiModule2 are devoid of
oriSV40, the virus titer is signi®cantly reduced to the ones
generated using an intact oriSV40/large T antigen replication
system (Table 3). We have therefore inserted a 168 bp
fragment spanning the oriSV40 into MCSIII of pLentiModule1
and pLentiModule2, respectively, resulting in pLentiModule3
and pLentiModule4. As quanti®ed from CHO-K1 transduc-
tions, oriSV40-containing pLentiModule derivatives achieve
Figure 8. Modular SIN lentiviral expression vectors. In order to facilitate the design of advanced lentiviral expression vectors, all cis-acting lentiviral
sequences are ¯anked by unique restriction sites in pLentiModule vectors (XhoI/NruI-U3-SrfI; SrfI-R-U5-y+-SD-SwaI/NsiI; SwaI/NsiI-cPPT-RRE-SA-MCS;
MCS-3¢LTRDU3-NdeI/NheI/SalI/XbaI). Unique restriction sites have also been placed within U3 (StuI, SbfI, PstI) and at the site of the deletion within
3¢LTRDU3 (PmeI, HpaI, BclI). In order to enhance virus production an oriSV40 (origin of replication of the Simian virus 40) has been placed 3¢ of the 3¢LTR
outside of the lentiviral expression unit. Test lentivectors pLentiModule2 and pLentiModule3 contain a PhCMV-driven EYFP expression cassette in the central
MCS.
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virus titers, which compares to aforementioned lentivectors
(Fig. 2, Table 3).
DISCUSSION
Since their discovery in the early 1980s, HIV-1 lentiviruses
were known to cause one of the most devastating epidemics in
industrialized countries in recent history (50,51). However,
the unique characteristic of HIV-1 to transduce and integrate
into the human genome owing to a set of accessory genes
managing nuclear import has brought this deadly virus into the
limelight of the gene therapy arena as most genetic defects in
humans reside in non-proliferating terminally differentiated
cells. As the ®rst development of replication-incompetent
HIV-1-based vectors to transduce mitotically inert rat neurons,
human skin ®broblasts and CD34+ cells (16,17), lentiviral
transduction technologies have witnessed a progress to the top
of currently most promising gene therapy initiatives.
Elimination of some 60% of its genome (including all
accessory genes) and re-assembly in multiply attenuated split-
genome packaging systems successfully addressed legitimate
initial safety concerns. The most advanced lentiviral transduc-
tion systems include a third-generation packaging system
consisting of a (i) gag-pol, (ii) rev and (iii) a vesicular
stomatitis virus-derived envelope protein (VSV-G) as well as
(iv) a SIN lentiviral expression vector. The split-genome
strategy dramatically reduces the emergence of replication-
competent recombinants and pseudotyping eliminates targeted
infection of CD4+ T lymphocytes as well as extension of the
cell tropism for therapeutic interventions (19). However, for
successful infection of some target tissues including the liver
some accessory proteins such as Vpr and Vif may be essential
and should be considered for the packaging set-up (9).
Typically, replication-incompetent lentiviral particles are
produced by co-transfecting a helper cell line with all
packaging and the lentiviral expression vector. However,
with pharmaceutical production of therapeutic lentiviruses in
mind a variety of different stable packaging cell lines have
been designed which produced replication-incompetent trans-
genic lentiviruses in a tetracycline-responsive manner
(20±23).
The lentiviral expression unit is the only genetic material
transferred to the target cells and encodes the desired
therapeutic transgene. This expression vector contains only
cis-acting sequences and is devoid of any lentiviral coding
sequences, which prevents signi®cant humoral immune
responses. Major improvements of lentiviral expression
vectors include: (i) elimination of enhancer sequences from
the 3¢LTR which results in complete loss of the 5¢LTR's
transcriptional capacity and the viral mobilization competence
upon integration of the provirus in the target chromosome
thereby increasing safety and minimizing interferences with
internal and chromosomal promoters in vivo and (ii) replace-
ment of 5¢LTR promoters by heterologous promoters to
achieve Tat-independent and/or tetracycline-responsive virus
production (23,25,26,49). Many of these state-of-the-art
lentivectors have been successfully used in pioneering gene
therapy studies for the treatment of many prominent human
diseases in animal models including Parkinson's disease and
metachromatic leukodystrophy (8,10).
Despite the dramatic progress in lentivector development in
recent years lentiviral expression con®gurations available
from the pioneering research groups have been rather
specialized and inconvenient for straightforward design of
multi-purpose lentivectors by a broad scienti®c community.
We have therefore designed a highly modular construction kit-
like expression platform based on the latest generation SIN
lentivectors for mono- and multicistronic expression in a
variety of cell lines and primary cells including, for the ®rst
time, ARCs. Also, to our knowledge, we report here the ®rst
lentiviral transduction into chicken embryos. This simple-to-
use multi-purpose lentivector expression platform, which is
compatible with any of the aforementioned packaging
concepts is expected to greatly facilitate the use of lentiviral
transduction technologies by a wider scienti®c community to
accelerate the advancement in gene therapy and tissue
engineering.
Figure 9. Transduction of pLentiModule-derived lentiviruses into various
insect, chicken, murine and human cell types as exempli®ed by a VSV-G-
pseudotyped pLentiModule3-derived lentivirus (pLentiModule4). The gene
coding for the EYFP was successfully transduced into Chinese hamster
ovary cells (CHO-K1), baby hamster kindney cells (BHK-21), human
®brosarcoma cells (HT-1080), human cervial adenocarcinoma cells (HeLa),
human hepatocellular carcinoma cells (HepG2), human chronic
myelogenous leukemia cells (K-562), bursal chicken cells (DT40) as well as
insect cells (SF9). pLentiModule4-derived lentiviruses also transduced glial
cells in hippocampal slice cultures (hippocampal slice) and primary ARC
(magni®cation 1003, hippocampal slice 503; ARC 4003).
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